INTERNATIONAL SEARCH REPORT

ational Application No
/BE2004/000124

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/519 A61K31/5377 A61K31/541 A61K45/06 C07D475/04
C07D475/08 C07D475/00 A61P37/00 A61P37/02 A61P37/06
A61P9/00 A61P25/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, PAJ, WPI Data, BIOSIS, EMBASE, MEDLINE, SCISEARCH, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/39129 A (WAER MARK JOSEPH ALBERT ; HERDEWIJN PIET ANDRE MAURITS M (BE); LEUVEN) 6 July 2000 (2000-07-06) page 1, line 4 - page 2, line 10 page 2, line 34 - page 3, line 12 page 4, lines 3-7 page 7, lines 31-34 page 8, lines 6-29 page 10, lines 6-31 page 12, lines 15-26 page 17, line 30 - page 18, line 13 page 19, lines 8-20 page 19, line 34 - page 20, line 14 page 20, lines 20-23 compounds 1,2,3,6,13-16,21-63,65,66 claims 1-8,13-17 ----- -/--	1-16, 20-24

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 April 2005	27/04/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Cielen, E

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MATTER HANS ET AL: "Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 14, 4 July 2002 (2002-07-04), pages 2923-2941, XP002313348 ISSN: 0022-2623	1-7
A	abstract page 2924, column 2, paragraph 3 compounds 264,265,246,247,301,303,305,306,310,311,313,315 compounds 317,318 page 2938, column 1, paragraphs 5,7 page 2938, column 2, paragraph 1	8-14
X	GB 785 353 A (MERCK & CO INC) 30 October 1957 (1957-10-30) page 1, lines 22-43 page 2, lines 72-87 page 2, lines 120-130 claims 1,8,10	1,2
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KALDRIKYAN, M. A. ET AL: "Pteridine derivatives. I. Synthesis of some substituted 6,7-diarylpteridines" XP002313350 retrieved from STN Database accession no. 1976:560035 abstract & ARMYANSKII KHIMICHESKII ZHURNAL , 29(4), 337-41 CODEN: AYKZAN; ISSN: 0515-9628, 1976,	1-6
X	YAO, QIZINENG ET AL: "Pteridines. Part CXIII. Protection of pteridines" HELVETICA CHIMICA ACTA , 86(1), 1-12 CODEN: HCACAV; ISSN: 0018-019X, 2003, XP008041327 compound 28	1

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/21619 A (PFLEIDERER WOLFGANG ; KOTSONIS PETER (DE); SCHMIDT HARALD (DE); FROEHL) 29 March 2001 (2001-03-29) page 1, lines 10-13 page 4, lines 19-25 page 5, line 1 - page 7, line 10 page 15, lines 11-30 page 16, lines 11-14 page 21, line 16 - page 23, line 27 claims 1-8	1-14, 20-22
A	NICOLAUS B J R: "Symbiotic Approach to Drug Design" DECISION MAKING IN DRUG RESEARCH, XX, XX, 1983, pages 173-186, XP002197412 the whole document	
T	EP 1 479 682 A (4 AZA BIOSCIENCE NV) 24 November 2004 (2004-11-24) page 2, paragraph 1-3 page 24, paragraphs 67,70,71 page 25, paragraphs 73,74 page 27, paragraphs 87,88	8-17, 20-25
X	ISRAEL, MERVYN ET AL: "Pyrimidine derivatives. VII. Some condensed derivatives of 2,4,5-triamino-6-methylthiopyrimidine" JOURNAL OF PHARMACEUTICAL SCIENCES , 54(11), 1626-32 CODEN: JPMSAE; ISSN: 0022-3549, 1965, XP008045079 compounds XIIIA,XIIIB,XIV page 1631, column 1, paragraph 4 - column 2, paragraph 1	1,2
X	DATABASE BEILSTEIN 29 November 1988 (1988-11-29), XP002324247 abstract; compound BRN1184281	1,2
X	ELLIOTT R D ET AL: "Synthesis of N-10-methyl-4-thiofolic acid and related compounds." JOURNAL OF MEDICINAL CHEMISTRY. MAY 1975, vol. 18, no. 5, May 1975 (1975-05), pages 492-496, XP002324245 ISSN: 0022-2623 compounds 10,17-19 page 495, column 1, paragraph 2 page 495, column 1, last paragraph - column 2, paragraph 3	1

-/--

INTERNATIONAL SEARCH REPORT

ational Application No
/BE2004/000124

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3 159 628 A (PACHTER IRWIN J ET AL) 1 December 1964 (1964-12-01) column 4, lines 13-15 column 4, lines 36,37 claims 1,5	1-3,8-10
X	EP 0 134 922 A (DR. KARL THOMAE GMBH) 27 March 1985 (1985-03-27) page 6, line 17 - page 7, line 4 examples 6,7,10,12,14,17,18 claims 1,9	1,2,5,6, 8,9,12, 13
X	EP 0 185 259 A (DR. KARL THOMAE GMBH) 25 June 1986 (1986-06-25) page 2, lines 16-24 page 7, line 28 - page 8, line 12 page 14, line 8 - page 15, line 4 examples 2,3,6-8,12 page 22, lines 23-26 page 23, lines 5-20 examples 16,18-21,23,26-29,33 claims 1,2,7	1,2,5,6, 8,9,12, 13
X	FROEHLICH LOTHAR G ET AL: "Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: Structure-activity relationship of antagonists of (6R)-5,6,7,8-tetrahydrobiopterin cofactor" JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 20, 7 October 1999 (1999-10-07), pages 4108-4121, XP002324246 ISSN: 0022-2623	1-7
A	abstract page 4108, column 2, paragraph 1 page 4109, column 1, paragraph 3 table 9 page 4113, column 2, paragraph 1 - page 4114, column 2, paragraph 1 page 4114, column 2, paragraph 3 page 4118, column 2, paragraph 5 - page 4119, column 1, paragraph 2	8-14
X	DE 19 21 308 A1 (C.H. BOEHRINGER SOHN) 7 January 1971 (1971-01-07) page 2, paragraph 1 page 13, lines 10,11 page 13, lines 1,2 page 13, line 15 - page 14, line 2	1,6,8,13

-/--

INTERNATIONAL SEARCH REPORT

tional Application No
/BE2004/000124

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 081 230 A (WEINSTOCK JOSEPH ET AL) 12 March 1963 (1963-03-12) column 1, lines 11-18 column 2, lines 3-27 example 24	1,5,8,12
X	DE 40 09 941 A1 (DR. KARL THOMAE GMBH, 7950 BIBERACH, DE) 2 October 1991 (1991-10-02) page 2, line 45 - page 3, line 15 page 3, lines 51,55 page 5, lines 25,26 claims 1,3,7,11	1,8,15, 16
X	WO 03/062240 A (FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH; EISENBRAND) 31 July 2003 (2003-07-31) page 1, lines 5-10 page 2, line 20 - page 4, line 17 examples 3,6 claims 1,2,13	1,6,8,13
X	US 2 940 972 A (ROCH JOSEF) 14 June 1960 (1960-06-14) column 1, lines 15-39 column 3, lines 16-29 examples 3,7 columns 9-14; compounds 8,10,12,19,25,26,30,33,38,39 claims 1,4,7,8	1,6,8,13
X	DD 267 495 A1 (AKADEMIE DER WISSENSCHAFTEN DER DDR,DD) 3 May 1989 (1989-05-03) page 1, paragraph 5 - last paragraph	1,8
X	US 3 859 287 A (PARISH ET AL) 7 January 1975 (1975-01-07) column 1, lines 16-58 column 4, lines 30-35 column 4, line 66 - column 5, line 2 examples VII,XVIX,XX column 21, line 64 - column 22, line 5 figures 6,7	1,8
X	SPICKETT R G W ET AL: "THE SYNTHESIS OF COMPOUNDS WITH POTENTIAL ANTI-FOLIC ACID ACTIVITY. PART I. 7-AMINO- AND 7-HYDROXY-PTERIDINES" JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1954, pages 2887-2891, XP008045137 ISSN: 0368-1769 compound III page 2892, paragraphs 4,5	1,4

-/--

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/32507 A (ASTRAZENECA AB; BONNERT, ROGER; WALTERS, IAIN) 25 April 2002 (2002-04-25) page 1, lines 3-5 page 1, line 31 - page 3, line 17 page 5, lines 6-15 page 6, lines 26,27 page 7, line 7 - page 8, line 29 page 9, lines 25-29	1,8,20, 22

INTERNATIONAL SEARCH REPORT

nternational application No.
PCT/BE2004/000124

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 20-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [X] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

1-7 (entirely), 8-15 (partially), 16-17 (entirely), 20-23 (partially) 24-25 (entirely)

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[X] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4, 7-11, 14-17, 20-25 (all partially)

A pteridine derivative having the general formula as defined in claim 1, wherein X represents an oxygen atom.
A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents an oxygen atom, as far as related to the prevention or treatment of immune and auto-immune disorders, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.
A method for the prevention or treatment of immune and auto-immune disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents an oxygen atom, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.

---

2. claims: 1-4, 7-11, 14-17, 20-25 (all partially)

A pteridine derivative having the general formula as defined in claim 1, wherein X represents a group with the formula S(O)m.
A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula S(O)m, as far as related to the prevention or treatment of immune and auto-immune disorders, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.
A method for the prevention or treatment of immune and auto-immune disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula S(O)m, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.

---

3. claims: 1-4 (partially), 5-6 (entirely), 7-17 (partially), 20-25 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pteridine derivative having the general formula as defined in claim 1, wherein X represents a group with the formula NZ.
A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula NZ, as far as related to the prevention or treatment of immune and auto-immune disorders, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.
A method for the prevention or treatment of immune and auto-immune disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula NZ, and optionally further comprising one or more immuno-suppressants and/or immunomodulator drugs.

---

4. claims: 8-11, 14, 20-22 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents an oxygen atom, as far as related to the prevention or treatment of cardiovascular disorders.
A method for the prevention or treatment of cardiovascular disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents an oxygen atom.

---

5. claims: 8-11, 14, 20-22 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula S(O)m, as far as related to the prevention or treatment of cardiovascular disorders.
A method for the prevention or treatment of cardiovascular disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula S(O)m.

---

6. claims: 8-14, 20-22 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula NZ, as far as related to the prevention or treatment of cardiovascular disorders.
A method for the prevention or treatment of cardiovascular disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula NZ.

---

7. claims: 8-11, 14, 20-22 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents an oxygen atom, as far as related to the prevention or treatment of disorders of the central nervous system.
A method for the prevention or treatment of disorders of the central nervous system comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents an oxygen atom.

---

8. claims: 8-11, 14, 20-22 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula S(O)m, as far as related to the prevention or treatment of disorders of the central nervous system.
A method for the prevention or treatment of disorders of the central nervous system comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula S(O)m.

---

9. claims: 8-14, 20-22 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula NZ, as far as related to the prevention or treatment of disorders of the central nervous system.
A method for the prevention or treatment of disorders of the central nervous system comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula NZ.

---

10. claims: 8-11, 14-15, 18, 20-23, 26 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents an oxygen atom, as far as related to the prevention or treatment of cell proliferative disorders, and optionally further comprising one or more antineoplastic drugs.
A method for the prevention or treatment of cell proliferative disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents an oxygen atom, and optionally further comprising one or more antineoplastic drugs.

---

11. claims: 8-11, 14-15, 18, 20-23, 26 (all partially)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula S(O)m, as far as related to the prevention or treatment of cell proliferative disorders, and optionally further comprising one or more antineoplastic drugs.
A method for the prevention or treatment of cell proliferative disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula S(O)m, and optionally further comprising one or more antineoplastic drugs.

---

12. claims: 8-15, 18, 20-23, 26 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8, wherein X represents a group with the formula NZ, as far as related to the prevention or treatment of cell proliferative disorders, and optionally further comprising one or more antineoplastic drugs.
A method for the prevention or treatment of cell proliferative disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20, wherein X represents a group with the formula NZ, and optionally further comprising one or more antineoplastic drugs.

---

13. claims: 8-15 (partially), 19 (entirely), 20-23 (partially), 27 (entirely)

A pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 8 and further comprising one or more antiviral drugs.
A method for the prevention or treatment of antiviral disorders comprising the administration of a pharmaceutical composition comprising as an active principle at least one pteridine derivative having the general formula as defined in claim 20 and further comprising one or more antiviral drugs.

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No
T/BE2004/000124

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0039129 A	06-07-2000	AT	277929 T	15-10-2004
		AU	770551 B2	26-02-2004
		AU	3042900 A	31-07-2000
		CA	2356380 A1	06-07-2000
		DE	69920757 D1	04-11-2004
		WO	0039129 A1	06-07-2000
		EP	1144412 A1	17-10-2001
		JP	2002533464 T	08-10-2002
		US	2004077859 A1	22-04-2004
GB 785353 A	30-10-1957	NONE		
WO 0121619 A	29-03-2001	DE	19944767 A1	29-03-2001
		AU	7517400 A	24-04-2001
		WO	0121619 A1	29-03-2001
		EP	1216246 A1	26-06-2002
		JP	2004522690 T	29-07-2004
		US	6844343 B1	18-01-2005
EP 1479682 A	24-11-2004	US	2003236255 A1	25-12-2003
		EP	1479682 A1	24-11-2004
		WO	2004104005 A2	02-12-2004
US 3159628 A	01-12-1964	NONE		
EP 0134922 A	27-03-1985	DE	3323932 A1	10-01-1985
		AT	39253 T	15-12-1988
		AU	565105 B2	03-09-1987
		AU	3009284 A	03-01-1985
		CA	1233179 A1	23-02-1988
		DD	229990 A5	20-11-1985
		DE	3475620 D1	19-01-1989
		DK	316284 A ,B,	03-01-1985
		EP	0134922 A1	27-03-1985
		ES	8503352 A1	01-06-1985
		ES	8601205 A1	16-02-1986
		FI	842622 A ,B,	03-01-1985
		GB	2143232 A ,B	06-02-1985
		HU	34487 A2	28-03-1985
		IL	72265 A	31-08-1987
		JP	60025991 A	08-02-1985
		NO	842631 A ,B,	03-01-1985
		NZ	208725 A	28-10-1988
		PH	22493 A	12-09-1988
		ZA	8404968 A	26-03-1986
EP 0185259 A	25-06-1986	DE	3445298 A1	12-06-1986
		AU	576924 B2	08-09-1988
		AU	5123285 A	19-06-1986
		CA	1252783 A1	18-04-1989
		DK	572685 A ,B,	13-06-1986
		EP	0185259 A2	25-06-1986
		ES	8707238 A1	01-10-1987
		FI	854862 A ,B,	13-06-1986
		GR	852996 A1	16-04-1986
		IL	77294 A	28-02-1989
		JP	61140585 A	27-06-1986
		NO	854965 A ,B,	13-06-1986

INTERNATIONAL SEARCH REPORT

Information on patent family members

tional Application No
/BE2004/000124

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0185259 A		NZ 214522 A	28-07-1988
		PH 24451 A	25-06-1990
		PT 81650 A ,B	01-01-1986
		ZA 8509462 A	29-07-1987
DE 1921308 A1	07-01-1971	BE 733488 A	24-11-1969
		FR 2009148 A5	30-01-1970
		NL 6907700 A	25-11-1969
US 3081230 A	12-03-1963	GB 936501 A	11-09-1963
		GB 941812 A	13-11-1963
		MY 10064 A	31-12-1964
DE 4009941 A1	02-10-1991	NONE	
WO 03062240 A	31-07-2003	DE 10202468 A1	30-09-2004
		WO 03062240 A1	31-07-2003
		EP 1467994 A1	20-10-2004
		US 2005054653 A1	10-03-2005
US 2940972 A	14-06-1960	NONE	
DD 267495 A1	03-05-1989	NONE	
US 3859287 A	07-01-1975	NONE	
WO 0232507 A	25-04-2002	AU 9615101 A	29-04-2002
		EP 1328319 A1	23-07-2003
		JP 2004511532 T	15-04-2004
		WO 0232507 A1	25-04-2002
		US 2004102447 A1	27-05-2004